Now showing items 1-10 of 10
Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis.
AIMS: To examine the association between socioeconomic status (SES) and disease-modifying therapy (DMT) prescribing patterns in people with relapsing-remitting multiple sclerosis (pwRRMS). METHODS: A cross-sectional analysis ...
SARS-CoV-2 and Multiple Sclerosis: Not all immune depleting DMTs are equal or bad.
(Wiley Online, 2020-05-08)
A major concern during the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic1 is the use of immunosuppressive therapies for the treatment of multiple sclerosis (MS) due to an increased risk of ...
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
BACKGROUND: SARS-CoV-2 viral infection causes COVID-19 that can result in severe acute respiratory distress syndrome (ARDS), which can cause significant mortality, leading to concern that immunosuppressive treatments for ...
B cells and multiple sclerosis spinal cord pathology
Synaptic loss in the multiple sclerosis spinal cord.
Disability in multiple sclerosis (MS) is considered primarily a result of axonal loss. However, correlation with spinal cord cross-sectional area - a predictor of disability - is poor, questioning the unique role of axonal ...
Detecting and predicting neutralization of alemtuzumab responses in MS.
OBJECTIVE: To test the hypothesis that antidrug antibodies (ADAs) against alemtuzumab could become relevant after repeated treatments for some individuals, possibly explaining occasional treatment resistance. METHODS: ...